|1.||Gangjee, Aleem: 11 articles (09/2015 - 05/2002)|
|2.||Matherly, Larry H: 11 articles (09/2015 - 03/2007)|
|3.||Hou, Zhanjun: 11 articles (09/2015 - 03/2007)|
|4.||Assaraf, Yehuda G: 10 articles (10/2014 - 01/2002)|
|5.||Zhao, Rongbao: 6 articles (02/2014 - 01/2004)|
|6.||Goldman, I David: 6 articles (02/2014 - 01/2004)|
|7.||McGuire, John J: 5 articles (04/2009 - 05/2002)|
|8.||Jansen, G: 4 articles (01/2014 - 09/2000)|
|9.||Cherian, Christina: 4 articles (11/2013 - 02/2012)|
|10.||Jansen, Gerrit: 4 articles (12/2011 - 01/2002)|
11/01/2010 - "Drug resistance is the main barrier to more effective treatment of cancers with antifolates; therefore, mechanisms of antifolate resistance and currently applied approaches to overcome it are also pointed out in the review."
09/01/2011 - "New patent disclosures reveal novel antifolate scaffolds, antifolates with improved drug-like properties and new strategies to effectively target cancer cells. "
11/01/1983 - "These studies demonstrated that, depending upon the mechanism of resistance, MTX-resistant human tumor cells may be effectively killed by antifolates with different routes of uptake into cells, or with a different enzyme target. "
10/01/2014 - "Furthermore, the recent availability of the crystal structures of FRα and FRβ in complex with folates and antifolates forms a realistic basis for the rational design and implementation of novel FR-targeted drugs for the treatment of cancer and inflammatory disorders. "
01/01/2014 - "Novel tumor-targeted antifolates related to PMX with selective membrane transport by PCFT over RFC are being developed. "
10/01/1998 - "In conclusion, the efficacy of novel antifolates against childhood leukemia cells can be tested with the in situ TS inhibition assay. "
04/30/2009 - "Since polyglutamylation of antifolates is crucial for their pharmacological activity in leukemia, loss of FPGS function results in decreased cellular levels of polyglutamylation-dependent antifolates and consequent drug resistance. "
03/01/2008 - "Now, after several years of administration of antifolates against malignancies and particularly leukemia, we are still trying to achieve a full understanding of the mechanisms of action and resistance to these agents. "
10/01/1998 - "For human CEM leukemia cell lines with well-defined mechanisms of resistance to MTX, in situ TS inhibition correlated with the growth-inhibitory effects of MTX and the novel antifolates (r = 0.86-0.93; P < 0.01). "
02/27/1998 - "Variable expression of RFC1 in human leukemia cell lines resistant to antifolates."
04/01/2007 - "Several previous clinical trials have shown that malignant pleural mesothelioma is responsive to antifolates. "
02/01/2002 - "These trials will help to define the role of these new antifolates in malignant pleural mesothelioma."
05/01/2013 - "Antifolates belong to the most effective cytotoxic drugs for malignant pleural mesothelioma (MPM) treatment. "
02/01/2002 - "The emerging role of antifolates in the treatment of malignant pleural mesothelioma."
07/01/1994 - "Folic acid antagonists are reported to have activity against mesothelioma. "
|4.||Sarcoma (Soft Tissue Sarcoma)
03/15/1992 - "Mechanisms of natural resistance to antifolates in human soft tissue sarcomas."
09/09/1991 - "These results indicate that the in situ TS assay and clonogenic assay may be used to predict anti-tumor efficacy of antifolates in vivo in this rat sarcoma."
11/01/1991 - "Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma."
01/01/1979 - "In tests conducted on 220 rats with transplantable sarcoma M-1 and intact animals acute toxicity, antineoplastic effect and the action on the blood system of tomizine, a new neoplastic drug of the group of the folic acid antagonists, were studied. "
09/09/1991 - "When tumor-cell suspensions were prepared from the rat sarcoma propagated in vivo, they were less sensitive to these antifolates, but the relative effectiveness of the 3 antifolates was similar: TMTX much greater than 10-EDAM greater than MTX. "
04/01/2009 - "4-Amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) is the prototype of a potentially therapeutically more selective class of antifolates for rheumatoid arthritis treatment. "
04/01/2009 - "Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs."
03/01/1993 - "Antifolates in rheumatoid arthritis: a hypothetical mechanism of action."
09/01/2008 - "C667T, and to a lesser extent A1298C polymorphisms, are also reported to influence the cytotoxic effect of fluoropyrimidines and antifolates providing support for their pharmacogenetic role in predicting the efficacy and the toxicity in cancer and rheumatoid arthritis patients. "
02/01/2006 - "Antimetabolites, especially antifolates, play an important role in the treatment of a variety of both malignant, and non-malignant diseases, such as rheumatoid arthritis, and bacterial and parasitic infections. "
|3.||Reduced Folate Carrier Protein
|4.||Folic Acid (Vitamin M)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)